Compare AstraZeneca plc (AZN) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs SoFi Technologies Inc — how do they compare? AstraZeneca plc trades at $169.37 (market cap $253.13B), while SoFi Technologies Inc trades at $18.17 (market cap $23.79B). The key difference: AstraZeneca plc is far larger — about 10.6× SoFi Technologies Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| AZN | SOFI | |
|---|---|---|
Market Cap | $253.13B | $23.79B |
Sector | Health | Financials |
52-Week High | $209.48 | $32.21 |
52-Week Low | $137.44 | $15.15 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SoFi trades at $18.13, down 3.46% today but up from its year-to-date low near $15. The stock is in a bullish technical trend with key support at $18 and resistance at $19. Fundamentally, revenue grew to $3.61B in 2025 with net income of $481.32M, though cash flow from operations remains negative. Recent news highlights AI acquisitions and ETF launches as growth catalysts.
The outlook is mixed: analyst consensus targets $22.43 (24% upside) with 33% buy ratings, but risks include persistent negative operating cash flow and high P/E of 40.29. Earnings beats in recent quarters support growth narrative, yet profitability sustainability and interest rate sensitivity are key investor concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
